Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by l. Oberic
Obinutuzumab Plus Dhap Followed by Autologous Stem Cell Transplantation (Asct) Plus Obinutuzumab Maintenance Provides a High MRD Response Rate in Untreated MCL Patients. Results of Lyma-101 Trial, a Lysa Group Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Obinutuzumab Plus Bendamustine in Previously Untreated Patients With CLL: A Subgroup Analysis of the GREEN Study
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Bortezomib Plus Dexamethasone Induction Followed by Autologous Stem Cell Transplantation in Multiple Myeloma: A Study From India
Asian Journal of Medical Sciences
Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase I Dose-Escalation Study of Venetoclax Plus Beam Followed by Autologous Stem Cell Transplant (Asct) for Chemoresistant, Relapsed/Refractory, or High-Risk Non-Hodgkin's Lymphoma (Nhl); Preliminary Results
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Brazilian Experience Using High-Dose Sequential Therapy (HDS) Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Malignant Lymphomas
Revista Brasileira de Hematologia e Hemoterapia
High Efficacy of Venetoclax Plus Obinutuzumab in Patients With Complex Karyotype (Ckt) and Chronic Lymphocytic Leukemia (Cll): A Prospective Analysis From the Cll14 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
High Dose Chemotherapy (HDT) With Busulfan, Melphalan and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Pediatric Patients (Pts) With High Risk Solid Tumors
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
The Immunologic Doublet of Lenalidomide Plus Obinutuzumab Is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/Ii Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
